The generation of drugs that modulate kinase activity has become a prime focus of the pharmaceutical industry. Cisbio, in partnership with Upstate, has made available the universal HTRF KinEASE assay for serine-threonine kinases (STKs). This article describes the use of this assay for kinase assay optimization and adaptation for high-throughput screening.
There is a constant need to improve high-throughput assay formats to generate accurate and rapid results for kinase screening. One potential alternative to radiometric methods involves the use of phosphospecific antibodies that specifically recognize the phosphorylated target of a kinase. In the past, the development of assays for STKs has often been slow, owing to the limited availability of highly specific antibodies for each phosphorylated STK substrate. A new alternative, HTRF KinEASE, was designed to streamline the assessment of many STKs using a simple noncompetitive assay format, involving just one antibody and defined peptide substrates.
HTRF KinEASE combines Cisbio's proprietary homogeneous timeresolved fluorescence (HTRF) technology with proprietary monoclonal antibodies and three STK peptide substrates developed by Upstate.
The antibody recognizes a phosphorylation epitope shared by the biotinylated peptides, and variation in the N-terminal sequence allows different STKs to be assessed.
In the assay described in Figure 1 , incubation of an STK with one of the three peptides is followed by the addition of a premixed solution of europium cryptate (Eu(K))-labeled antibody and fluorophoreconjugated streptavidin (SA-XL665). A readout can be made after just 1 h of incubation, and the signal is stable at room temperature for at least 24 h. Each of the 72 kinases listed in Table 1 has been validated and the most appropriate substrate has been determined. Depending on the kinase tested, HTRF KinEASE allows a signal-to-background ratio of between 5 and 30 to be obtained using 2 ng/well kinase, 1 µM substrate, 100 µM ATP, 30-min enzymatic reaction, 62.5 nM SA-XL665 and a ready-to-use solution of STK antibody-Eu(K). Figure 2 shows the signal-to-background ratio obtained in a 20-µl final volume for PKCζ, PAK3 and IKKβ kinase assays using the optimal substrate.
Guidelines for assay optimization
Every step of the procedure has been optimized to generate rapid results.
For each new kinase, the first step involves identifying the optimal substrate with the Discovery kit, which contains all three substrates. In some cases, more than one substrate is compatible with a given STK, 
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APPLICATION NOTES
and the substrate that produces the highest signal should be selected for further investigation. The kinase is titrated using the optimal substrate to determine its optimal concentration for screening. We recommend choosing a kinase concentration at 80% efficient concentration (EC 80 ) of the titration curve to maximize the signal. Enzyme kinetics should be performed to determine the optimal incubation time. After fixing these parameters, ATP K M , substrate K M and the optimal streptavidin:biotin ratio can be determined. Finally, the assay is validated for screening using a reference inhibitor.
As an example, we evaluated inhibition of the kinase Aurora A by staurosporine using an enzyme concentration of 2 ng/well. We 
Optimization of the screening conditions
The following additional parameters can be tested to enhance assay quality:
1. With HTRF KinEASE, assays can be run at any ATP concentration.
This feature is valuable to demonstrate ATP-competitiveness for lead compounds by increasing ATP concentrations up to 5 mM. In summary, HTRF KinEASE combines several advantages for kinase screening. By using antibody-based detection, HTRF KinEASE offers the high reliability of specific and sensitive immunodetection. In addition, the use of universal substrates greatly simplifies the assay development phase, as a common assay format is being applied. Given the high-throughput capabilities of HTRF, this new platform represents an ideal solution for kinase profiling and screening. Additional information is available on our company website (http://www.htrf.com).
HTRF is a registered trademark of Cisbio international, and KinEASE is a registered trademark of Upstate USA, Inc.
This article was submitted to Nature Methods by a commercial organization and has not been peer reviewed. Nature Methods takes no responsibility for the accuracy or otherwise of the information provided. Figure 2 ⏐ Signal-to-background measurements obtained with HTRF KinEASE assays using three different STKs: PKCζ, PAK3 and IKKβ. Increasing kinase concentrations were tested using the optimal substrate. The concentration of substrate (1 µM), ATP (100 µM), SA-XL665 (62.5 nM) and STK antibody-Eu(K) and incubation time for the enzymatic step (30 min) were held constant.
